Bayer Aktiengesellschaft

Bayer Intellectual Property Gmbh

Bayer Pharma Aktiengesellschaft

Bayer Schering Pharma Ag

Bayer Healthcare Aktiengesellschaft

Michael Härter

Frank Wunder

Johannes-Peter Stasch

Michael Hahn

Elke Stahl

Andreas Knorr

Claudia Hirth-Dietrich

Klemens Lustig

Pierre Wasnaire

Joachim Schuhmacher

Peter Kolkhof

Christoph Gerdes

Raimund Kast

Stefan Heitmeier

Anja Buchmüller

Niels Lindner

Martina Delbeck

Hartmut Beck

Marcus Bauser

Karl-Heinz Schlemmer

Hilmar Bischoff

Delf Schmidt

Dieter Lang

Dirk Kosemund

Nils Griebenow

Jörg Keldenich

Bernd Buchmann

Lars Bärfacker

Josef Pernerstorfer

Walter Hübsch

Hanna Tinel

Andrea Vaupel

Manoj Patel

Tobias Wunberg

Frank Süβmeier

Peter Ellinghaus

Ulrich Rester

Swen Allerheiligen

Susanne Greschat

Bernd Kalthof

Karl-Heinz Thierauch

Beatrix Stelte-Ludwig

Mark Jean Gnoth

Eva-Maria Becker

Klaus Urbahns

Johannes Köbberling

Hartmut Schirok

Cristina Alonso-Alija

Gunter Karig

Joachim Telser

Mario Lobell

Stefan Weigand

Haruka Shimizu

Klaus Münter

Holger Hess-Stumpp

Timo Flessner

Stephan Siegel

Georges Von Degenfeld

Markus Albers

Frank Süssmeier

Ulf Brueggemeier

Antje Kahnert

Elke Dittrich-Wengenroth

Julia Strassburger

Hannah Jörißen

Arnel B Concepcion

Stephen James Boyer

Sylvia Grünewald

Hannah Jöriβen

Philip Wickens

Ellalahewage Sathyajith Kumarasinghe

Uwe Saatmann

Mélanie Héroult

Kerstin Unterschemmann

Melanie Heroult

Kerstin Berhörster

Uwe Saatman

Patrick Paulus

Martin Raabe

Jens Ergüden

Susanne Zuleger

Frank Süßmeier

Ajay Kumar Bhargava

Susanne Greschat-Schade

Kerstin Berhoerster

The present application relates to novel thieno[2,3-d]pyrimidine-2,4-dione ('thienouracil') derivatives bearing a particular type of (azaheterocyclyl)methyl substituent, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of pulmonary and cardiovascular disorders and of cancer.

Heterocyclylmethyl-thienouracile as antagonists of the adenosine-A2B-receptor

The present application relates to novel 2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxamide derivatives ('thienouracil'-carboxamides), to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases and to their use for the preparation of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of pulmonary and cardiovascular disorders.

Cyclic thienouracil-carboxamides and use thereof

The present application relates to novel 1-phenyl-1H-imidazo[1,2-b]pyrazole derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular angiogenic disorders and hyperproliferative disorders, where neovascularization plays a role, such as, for example, neoplastic disorders and tumor disorders. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.

Substituted phenylimidazopyrazoles and their use

This invention relates to novel heteroaryl substituted pyrazole compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients or therapeutic measures.

Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis

The present application relates to novel substituted 1-[3-(heterocyclyl)benzyl]-1H-pyrazole derivatives, to processes for preparation thereof, to use thereof for treatment and/or prevention of diseases and to use thereof for production of medicaments for treatment and/or prevention of diseases, more particularly for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be effected in the form of monotherapy or else in combination with other medicaments or further therapeutic measures.

Substituted heterocyclylbenzylpyrazoles and use thereof

The invention relates to aryl-substituted heterocycles, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of thromboembolic disorders.

Aryl-substituted heterocycles, and use thereof

The invention relates to novel substituted oxazolidinones, to processes for preparation thereof, to the use thereof for treatment and/or prophylaxis of diseases, and to the use thereof for producing medicaments for treatment and/or prophylaxis of diseases, especially of thromboembolic disorders.

Substituted oxazolidinones and their use

The invention relates to compounds of formula (I) and their salts and stereoisomers in which the variables are as defined in the description and claims, for producing medicaments used in the treatment of cardiovascular and other diseases. Such compounds, processes for preparing them, compositions containing them, and methods of using them are claimed.

Substituted aminodicarboxylic acid derivatives having pharmaceutical properties

This invention relates to methods for treating cardiovascular disorders selected from heart failure, thromboembolic disorders, venous diseases, and fibriotic disorders other than fibrosis of the liver, comprising administering an effective amount of a compound of formula (I) wherein the several variables are as defined in the specification and claims.

Halogen-substituted aminodicarboxylic acid derivatives

The present application relates to novel tetrahydrobenzo[d]azepin-2-one derivatives, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for producing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular disorders, especially of dyslipidaemias, arteriosclerosis, restenosis and ischaemias.

Tetrahydrobenzo[d]azepin-2-one derivatives and the use thereof for treating cardiovascular diseases

The present invention relates to isophthalic acid derivatives, to a process for their preparation and to their use for producing medicaments for the treatment and/or prophylaxis of diseases in humans and animals, in particular of cardiovascular disorders.

Isophthalic acid derivatives

This invention relates to methods for treating heart failure, thromboembolic disorders, and pulmonary fibrosis, comprising administering an effective amount of a compound of formula (I) in which the several variables are as defined in the specification and claims.

Methods for treating heart failure, thromboembolic disorders, and pulmonary fibrosis

The present invention relates to biphenyl and biphenyl-analogous compounds, their preparation and use as pharmaceutical compositions, as integrin antagonists and in particular for the production of pharmaceutical compositions for the treatment and prophylaxis of cancer, arteriosclerosis, restenosis, osteolytic disorders such as osteoporosis and ophthalmic diseases. The compounds according to the invention have the formula (1) wherein

Biphenyl and biphenyl-analogous compounds as integrin antagonists

Compounds of the general formula (I)wherein Rrepresents halogen, Rand Rrepresent H or halogen, and Rrepresents C-cycloalkyl or optionally substituted phenyl, pharamceutical compositions containing such materials, and methods of using such materials in the treatment of various diseases are disclosed and claimed.

Halogen-substituted amino dicarboxylic acid derivatives as medicaments for treating cardiovascular diseases

The invention relates to compounds of the general formula (I)wherein Rrepresents H, halogen, or OCF; Rand Reach represents H or halogen; Rrepresents C-alkyl, C-cycloalkyl, CF, OCF, F, Cl, OMe, or optionally substituted phenyl; V represents O, CHO, OCF, or O&#x2014;C-alkyl-O; and W represents CHor CHCH. A process for making such compounds, pharmaceutical compositions containing them, and methods of treatment of various conditions using them are also disclosed and claimed.

Derivatives of dicarboxylic acid having pharmaceutical properties

Growing community of inventors

Leverkusen, Germany

Michael Härter